[18F]FDG PET/CT features for the molecular characterization of primary breast tumors Lidija AntunovicFrancesca GallivanoneIsabella Castiglioni Original Article 15 July 2017 Pages: 1945 - 1954
Quantification: there is more to worry about than good scanner hardware and reliable calibration Jörg KotzerkeJörg van den Hoff Editorial Commentary 19 August 2017 Pages: 1955 - 1957
Elevated tumor-to-liver uptake ratio (TLR) from 18F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection Jun HuangLiang HuangMeijin Huang Original Article Open access 15 August 2017 Pages: 1958 - 1968
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial Ali SalavatiFenghai DuanAbass Alavi Original Article 08 July 2017 Pages: 1969 - 1983
Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection Jeong Won LeeSang Hyun HwangMijin Yun Original Article 11 July 2017 Pages: 1984 - 1994
Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma Yong-il KimYong Joong KimKeon Wook Kang Original Article 20 June 2017 Pages: 1995 - 2003
Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff Ana Reyes Romero-LluchJuan Ignacio Cuenca-CuencaElena Navarro-González Original Article 23 June 2017 Pages: 2004 - 2013
Interim FDG-PET in lymphoma, a questionable practice in hematology Hugo J. A. AdamsThomas C. Kwee Editorial Commentary 31 July 2017 Pages: 2014 - 2017
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma Julien LazaroviciMarie TerroirDavid Ghez Original Article 21 June 2017 Pages: 2018 - 2024
The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma Ismaheel O. LawalNozipho E. NyakaleMike M. Sathekge Original Article 28 June 2017 Pages: 2025 - 2033
Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial Stéphanie BeckerThomas VermeulinStéphane Lepretre Original Article 21 July 2017 Pages: 2034 - 2041
Early identification of MCI converting to AD: a FDG PET study Marco PaganiFlavio NobiliFabrizio De Carli Original Article 29 June 2017 Pages: 2042 - 2052
18F-Florbetaben PET beta-amyloid binding expressed in Centiloids Christopher C. RoweVincent DoréVictor L. Villemagne Original Article Open access 22 June 2017 Pages: 2053 - 2059
A new integrated dual time-point amyloid PET/MRI data analysis method Diego CecchinHenryk BarthelFranco Bui Original Article 04 July 2017 Pages: 2060 - 2072
18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage Silvia MorbelliMatteo BaucknehtFlavio Nobili Original Article 07 August 2017 Pages: 2073 - 2083
Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F–DOPA PET Giovanni MoranaArnoldo PiccardoAndrea Rossi Original Article 27 July 2017 Pages: 2084 - 2093
Bone SPECT/CT in the postoperative spine: a focus on spinal fusion Khulood Al-RiyamiGopinath GnanasegaranJamshed Bomanji Review Article 05 July 2017 Pages: 2094 - 2104
Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis Matthijs C. F. CysouwGerbrand M. KramerOtto S. Hoekstra Review Article Open access 04 August 2017 Pages: 2105 - 2116
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging Sara SheikhbahaeiAli Afshar-OromiehSteven P. Rowe Review Article 01 August 2017 Pages: 2117 - 2136
Dosimetry in clinical radionuclide therapy: the devil is in the detail Francesco GiammarileKristoff MuylleWim Oyen Letter to the Editor 10 September 2017 Pages: 1 - 3
Measurement uncertainty and clinical impact of target-to-background ratios derived by interim FDG-PET/CT in Hodgkin lymphoma: reply to Laffon and Martan Salvatore AnnunziataMaria Lucia CalcagniVittoria Rufini Letter to the Editor 06 September 2017 Pages: 2140 - 2141
About the specificity of radiotracers for prostate cancer Michael Soussan Letter to the Editor 07 August 2017 Pages: 2142 - 2143
Single high dose versus repeated bone-targeted radionuclide therapy K. Liepe Letter to the Editor 31 August 2017 Pages: 2144 - 2145
Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET Shinsuke SasadaHiroaki KuriharaKenji Tamura Image of the Month 03 August 2017 Pages: 2146 - 2147
A rare case of thymoma first detected on gallium-68 PSMA PET/CT Hian Liang HuangAngela Renayanti DharmawanSue Ping Thang Image of the Month 01 August 2017 Pages: 2148 - 2149
Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA Murat Fani BozkurtIrene VirgoliniStefano Fanti Erratum 30 August 2017 Pages: 2150 - 2151